Brief: Knight Therapeutics Q2 Revenue CAD 144.212 Million Vs. IBES Estimate CAD 125 Million
06/08/2026 11:31
BRIEF-Knight Therapeutics Q2 Revenue CAD 144.212 Million Vs. IBES Estimate CAD 125 Million Aug 06 (Reuters) - Knight Therapeutics Q2 net income CAD -3.361 million.
- Q2 operating expenses CAD 60.655 million
- outlook FY revenue CAD 540-560 million vs. IBES estimate CAD 519.9 million
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil